Tibet Pharmaceuticals, Inc. (Nasdaq: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, similar to companies like China Nuokang Bio-Pharmaceutical Inc. (Nasdaq: NKBP) and China Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN), recently reported that the transcripts from its first quarter conference call were now available online.

Tibet Pharmaceuticals, Inc. (NASDAQ:TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, recently announced the availability of the transcript for its first quarter 2011 earnings conference call, held on May 17th.

During the conference call Taylor Guo, Tibet Pharmaceutical’s Chief Executive Officer, stated, “With our modern 52,000 square-foot facility, and our unique location in the Qinghai-Tibet Plateau and our five SFDA approved medicines, Tibet Pharmaceuticals is committed to meeting the greater demand for Traditional Chinese Medicine.”

“During the first quarter Tibet achieved the milestone event of becoming a NASDAQ listed company and raising $16.5 million in our Initial Public Offering,” continued Mr. Guo. “As we move into the second quarter of 2011, we expect to further increase marketing and advertising for our growing portfolio of traditional Tibetan medicines, with a particular focus on organic growth and accretive acquisitions.”

Throughout the conference call Tibet Pharmaceutical’s CEO spoke about the company’s portfolio of traditional Tibetan medicine products, its operations and production capacity and full details surrounding its revenue and earnings numbers for the fiscal first quarter ended March 31, 2011.

Interested parties are encouraged to read the full transcript of the conference call, available here: http://www.trilogy-capital.com/autoir/tbet_autoir.html

About Tibet Pharmaceuticals, Inc.

Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ:TBET – News) is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals’ products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company’s 52,000 sq. ft. GMP-certified manufacturing facilities are located.  The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.

For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video.

For more information on Tibet Pharmaceuticals, please visit:

http://www.tibetpharmaceuticals.com

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. Specifically, references herein to contemplated growth in company revenues and/or earnings are forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

I believe we’ll look back at Thursday as the Tipping Point for China Small Cap stocks. It’s happening a little faster than I thought it would, and that’s great for us believers who want to be opportunistic.

If you were following this tome during the February/March bloodbath, you will recall I predicted the demise of all things smaller and China if China Media Express (CCME) turned out to be fraudulent. While the jury is still out on that one, it’s obvious there’s Trouble in River City.

Post CCME any blogger who could publish a fabricated report could knock 40% off a stock overnight. You could see the shorts piling on in advance of the “to be released” Cyber Smear. The legitimate researchers made a fortune identifying the fraud, but there have clearly been some abuses on that side of the ledger.

The market assumed every China based small cap was fabricating all its numbers, and priced accordingly. I believe about 1/3 of the China small caps are publishing numbers with some level of inaccuracy, so there are still problems to deal with.

Here’s the chart of the stock that I believe is turning the tide:

China Biotics is looking like the hero we have needed. This stock has remained on my buy list through the blood bath as I had cautious faith. CHBT has rebounded beautifully, and has recaptured nearly all the loss from Feb/March.

On Thursday morning, Citron Research accused them of fabricating their numbers, and the stock swooned. I sold my position as I watched it drop, did some research, watched it trade, and bought it back.

Citron references a research report, complete with pictures and all sorts of accusations of fraud. This report had already been released in early March, and they were just bringing it back up.

I read the report, but then I looked a little further. No author claims to have written the report, and there’s a claim the report is associated with the China Economic Review.

So, I went to www.chinaeconomicreview.com, and found a rather robust web site that appears to be a very legitimate source of information.

Yet, when I searched the site using the words “China Biotics”, there were no search results. I also perused a few of the articles, and learned everyone one of them has an identified author.

If this wasn’t enough, the stock’s behavior told me all I wanted to know. On Thursday, the stock traded a whopping 1.742 million shares, dropped 20% briefly, then rebounded in a big way to close nearly where it started.

Friday in a down market, CHBT made a new 2 month high of $12, and appears to be right back on track to move even higher. If you had the courage, you could have bought this one at $8 less than a month ago.

Now, if you’re long, this looks great. However, if you’re short this stock, you do not like Thursday’s action one bit, and you might be moved to close out your short position as it’s not worth the risk of holding.

Thursday’s action in CHBT is, in my view, the likely Tipping Point for the short sellers in the China Small Cap space. The smear simply didn’t work.

I bought CHBT back a little higher than where I sold it. Traders use the term “Whipsawed” by the market, but I think I made the right move.

I still believe this one is going to $20. But, let’s move on to my new #1 China small cap pick for 2011:

For my #1 China small cap stock for 2011, sign up for a trial subscription by visiting www.emergingchinastocks.com.

Warmest Regards,

Larry Isen

EastBridge Investment Group, Inc. (OTCBB: EBIG), a provider of financial services to emerging public companies in Asia, with clients similar to companies like Chinacast Education Corporation (Nasdaq: CAST) and China Education Alliance, Inc. (NYSE: CEU), recently entered into a consulting agreement with Cambium Learning Group to help it identify joint ventures in China.

EastBridge Investment Group (OTCBB:EBIG) today announced it has entered into a consulting agreement with Cambium Learning Group, Inc., a Nasdaq listed company based in Dallas, Texas.

Mr. Keith Wong, CEO of EastBridge, commented, “Cambium is a great company with a rich suite of products for online applications. Many of their K-12 products can be adapted to students in China, which has a total elementary, junior and high school student population of more than 200 million. We are very excited to be retained as a consultant to help them seek out opportunities in China for joint ventures, partnerships and merger & acquisition (M&A) work. We have substantial experience in China to help our clients achieve their expansionary goals.”

To learn more about Cambium, go to: www.cambiumlearning.com

EastBridge Investment Group focuses on high-growth companies in Asia, offering IPOs, Joint Ventures and Merchant Banking services. The Company targets industries in the education, internet, energy, mining and service sectors. To learn more about EastBridge Investment Group go to our web site: www.EbigCorp.com. To receive EBIG’s email alert, send a blank email to info@EbigCorp.com. Join us on Facebook at the following link: http://www.facebook.com/ebigcorp.

Forward-Looking Statements: Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential,” or “continue,” or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.

Asia Carbon Industries Inc. (OTCBB: ACRB), a China-based producer of a series of high-quality carbon black products, similar to companies like Cabot Corporation (NYSE: CBT) and Tokai Carbon Co., Ltd. (TYO: 5301), recently reported first quarter revenues that increased 154% and net income that jumped 564%.

Asia Carbon Industries, Inc. (OTC.BB:ACRB) (“Asia Carbon,” or the “Company”) today announced its earnings for the quarter ended March 31, 2011. The Company, whose shares trade in the U.S. under the stock symbol “ACRB,” filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on May 16, 2011.

Highlights of First Quarter 2011 Financials

• Revenues for the first quarter of 2011 increased 154% to $13.44 million in 2011, from $5.29 million for the same period in 2010.
• Gross profit increased 302% to $3.18 million in the first quarter of 2011 from $0.79 million for the same period in 2010.
• Net income for the first quarter of 2011 increased 564% to $2.1 million in 2011 from $0.32 million for the same period in 2010.
• Earnings per share were at $0.04 for the first quarter of 2011, compared to $0.01 for the same period in 2010.
• Weighted average basic shares outstanding for the first quarter in 2010 were 50,608,077, a 16% increase, as compared to 43,678,272 for the same period in 2010.

The Company’s sales for the three months ended March 31, 2011 totaled $13,441,516, an increase of $8,146,643, or 154%, compared to $5,294,873 for the three months ended March 31, 2010. The increase in sales was primarily attributed to the expansion in sales of the Company’s two newest products; N220-W, a wet-process carbon black, which launched in November of 2010, and naphthalene oil, which began selling in July 2010. Together, these two products accounted for 50% of revenue for the quarter and 82% of the increase in sales in the three months ended March 31, 2011.

During the three months ended March 31, 2011, the Company sold 5,463 metric tons of N220-W, generating revenue of $6,245,563 and naphthalene oil accounted for $448,075 in revenue from 500 metric tons of product sales for the quarter. Sales generated by the Company’s three dry process carbon black products, N330, N660 and N220-D accounted for $6,747,878 in sales.

The average sales price of all carbon products was $1,070 per metric ton during the first quarter of 2011, an increase of $299 per ton, or 42%, from $771 per ton during the first quarter of 2010.

Gross profit for the three months ended March 31, 2011 was $3,181,432, an increase of $2,390,771, or 302%, compared to $790,661 in the comparable period of 2010. The gross profit margin also increased, to 24% for the quarterly period ended March 31, 2011, from 15% for the same period in 2010, primarily as a result of the increased percent of sales from the higher margin wet process product and sale of naphthalene oil.

Net income was $2,105,473 for the three months ended March 31, 2011, an increase of $1,788,205, or 564%, compared to $317,268 for the same period in 2010. Again, the increase in net income is the result of the contribution of N220-W and naphthalene oil.

Yao Guoyun, Asia Carbon’s Chairman of the Board and Chief Executive Officer, commented, “We are very excited to report our first quarter results to our shareholders. The Company’s performance is a direct result of the successful implementation of the expansion plans we laid out at the time we brought Asia Carbon public; expanding our overall manufacturing capacity and transforming our existing production lines from dry-process to the higher quality wet-process production.”

Ms. Guoyun went on to say, “Demand for our products remains strong, particularly for N220-W, and we are hopeful that our continued growth will be well received by the public markets as we look to them for capital to facilitate the further expansion of our manufacturing and distribution capabilities.”

Ms. Guoyun commented further on the Company’s transition from a private to a public company, saying, “We became a public company through a registration statement on Form S-1 rather than a reverse merger, and while it was a somewhat slower process, our management team felt this was the appropriate approach for Asia Carbon and its shareholders. We have always, and will continue to adhere to the rules and regulations associated with being a public company in the United States.”

About Asia Carbon Industries, Inc.

Asia Carbon Industries Inc. is a China-based producer of a series of high quality carbon black products under the brand name “Great Double Star.” The Company was established in 2003 in Shanxi, China’s highest coal producing province. Asia Carbon is one of the top ten carbon black producers in the province and has established relationships with a high-profile customer base. The Company went public in 2010 through a registration statement on Form S-1 which was declared effective by the SEC on October 26, 2010, and is currently in the process of expanding its manufacturing capacity to meet the anticipated demand.

This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.

Forward-looking statements:

The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as “anticipate,” “appear,” “believe,” “could,” “estimate,” “expect,” “hope,” “indicate,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would,” and other variations or negative expressions of these terms, including statements related to expected market trends and the Company’s performance, are all “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.